Navigation Links
DURECT to Present at the Cowen and Company Healthcare Conference
Date:3/1/2010

CUPERTINO, Calif., March 1 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the Cowen and Company 30th Annual Healthcare Conference on Monday, March 8 at 3:15 pm Eastern Time.  The conference is being held at the Marriott Copley Place in Boston.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at  www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

Back to top

RELATED LINKS
http://www.durect.com

'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
2. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
3. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
4. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
5. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
6. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
7. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
8. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
9. Stryker to Present at Investor Conference
10. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
11. Hill-Rom to Present at the Canaccord Adams Musculoskeletal Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
(Date:6/7/2017)... Md. , June 7, 2017  Novavax, Inc., (Nasdaq: ... second of two Phase 2 trials of its RSV F ... of child bearing age have been published in the journal ... publication have been shared in prior scientific conferences). The Company ... in April 2014. Novavax is developing the RSV F Vaccine ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, ... with the Fertility Center of California, is pleased to announce the addition of ... and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used ...
(Date:6/26/2017)... ... 2017 , ... Maryland’s soybean farmers have improved the sustainability ... the United Soybean Board. , Thanks to the responsible use of technology ... on less land per bushel, the report says. The United Soybean Board’s “Soy ...
(Date:6/26/2017)... ... June 26, 2017 , ... LARKR™ , an innovative new smartphone ... state across the country to join its online treatment platform. , Launching in ... reach a substantially greater number of people in need nationwide, and to supplement their ...
(Date:6/26/2017)... ... , ... KICKICO , a protocol built on Ethereum for more transparent ... issues within funding campaigns. KICKICO developers are testing the platform, which will launch for ... of funds through the power of many - has been around for about ten ...
(Date:6/25/2017)... ... , ... FCPX LUT Vintage Volume 2 for Final Cut Pro X allows ... 2 contains 60 different color-grade presets, giving editors multiple options for adding different color ... out subjects, plus much more. FCPX LUT Vintage Volume 2 is designed for any ...
Breaking Medicine News(10 mins):